Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Ying Zhao *Department of Laboratory Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.ORCID 0000-0002-7093-1121
Lijiang Chen *Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Dingding LiDepartment of Laboratory Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Xiurong DingDepartment of Clinical Laboratory, Beijing You'an Hospital, Capital Medical University, Beijing, People's Republic of China.
Yunsong YuDepartment of Infectious Diseases, Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.ORCID 0000-0003-2903-918X
Zhonghao WangDepartment of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
Yingchun XuDepartment of Laboratory Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Lina GuoDepartment of Laboratory Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.ORCID 0000-0003-4812-8663
Funding
National High Level Hospital Clinical Research Funding 2022-PUMCH-C-052
6 · The paper itself
Abstract
This study evaluated the diagnostic performance of a chemiluminescence immunoassay (CLIA) for detecting the IMPORTANCE: This study demonstrates that the novel chemiluminescence immunoassay (CLIA) and the conventionally used LFA have a comparable performance in the detection of glucuronoxylomannan in cerebrospinal fluid (CSF) among patients with cryptococcosis. It enables tracking antigen concentration changes during treatment, providing preliminary reference for therapeutic monitoring.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evaluation of the performance of a novel chemiluminescence immunoassay for cryptococcal antigen detection. · full record | OpenQuestion